Jansen, Anouk M. E. http://orcid.org/0000-0002-4736-6515
Snijdelaar, Kim
Keizer, Ron J.
Spriet, Isabel
Dreesen, Erwin
Brüggemann, Roger J. M.
ter Heine, Rob
Article History
Accepted: 13 February 2024
First Online: 26 March 2024
Declarations
:
: Roger J.M. Brüggemann has served as consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, and Pfizer, Inc., and has received unrestricted research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc. All contracts and payments were through his institution. Ron J. Keizer is an employee and stockholder of InsightRX, a company developing precision dosing software. Anouk M.E. Jansen, Kim Snijdelaar, Isabel Spriet, Erwin Dreesen, and Rob ter Heine have no conflicts of interest to declare in relation to the current work.
: No funding or sponsorship was received for this study or publication of this article.
: The datasets analyzed during the current study are available from the corresponding author on reasonable request and following legal approval.
: The Medical Ethics Committee of the Radboud University Medical Center, Nijmegen, The Netherlands, waived the necessity to obtain informed consent from the patients for whom data were retrospectively collected. The ethical approval statement for the previously performed prospective study has been published elsewhere [CitationRef removed, CitationRef removed].
: AJ, RB, and RtH conceptualized and designed the study; AJ and KS performed data collection; AJ performed the analyses and interpreted the results with RtH and RB; and AJ wrote the first draft of the manuscript. All authors critically reviewed the manuscript and approved the final version.
: Not applicable.
: Not applicable.
: Model codes are available through the Supplementary Materials.